News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Applied Therapeutics Inc
(NQ:
APLT
)
6.340
+0.260 (+4.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Applied Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Applied Therapeutics Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
July 31, 2024
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised...
Via
Benzinga
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
July 16, 2024
Via
Benzinga
Applied Therapeutics Added to Russell 3000® Index
July 01, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics: Q4 Earnings Insights
March 06, 2024
Via
Benzinga
Top 4 Health Care Stocks That May Keep You Up At Night This Month
June 11, 2024
Via
Benzinga
APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024
May 09, 2024
APLT stock results show that Applied Therapeutics met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Applied Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
April 15, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
April 04, 2024
From
Applied Therapeutics
Via
GlobeNewswire
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
April 01, 2024
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates...
Via
Benzinga
Exposures
Product Safety
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
April 01, 2024
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 01, 2024
Via
Benzinga
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 01, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's After-Market Session
March 29, 2024
Via
Benzinga
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
March 28, 2024
From
Applied Therapeutics
Via
GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
March 06, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 28, 2024
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via
Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
February 28, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder
February 28, 2024
Applied Therapeutics surges as FDA grants Priority Review to govorestat (AT-007) for Galactosemia treatment. If approved, it would be the first medication for Galactosemia. APLT also submits MAA to...
Via
Benzinga
Exposures
Product Safety
Why Is Coupang (CPNG) Stock Up 4% Today?
February 28, 2024
Coupang stock is rallying on Wednesday as investors in CPNG celebrate the company beating out EPS and revenue estimates for Q4.
Via
InvestorPlace
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
February 28, 2024
Via
Investor Brand Network
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
February 28, 2024
Applied Therapeutics stock is rising higher on Wednesday alongside heavy trading of APLT following an update from the FDA.
Via
InvestorPlace
Applied Therapeutics Announces $100 Million Private Placement
February 28, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
February 28, 2024
From
Applied Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 16, 2024
Via
Benzinga
Why Is Rare Disease-Focused Applied Therapeutics Stock Trading Higher Today?
February 15, 2024
Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD Deficiency...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.